Companies › Arbor Biotechnologies
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABO-101 Gene therapy delivering a functional copy of the AGXT gene to hepatocytes | AGXT | Phase 1 | Primary Hyperoxaluria Type 1 (PH1) | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06839235 | ABO-101 | Phase 1 | Primary Hyperoxaluria Type 1 (PH1) | Metabolic and endocrine | Mar 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.